Jump to content

Propylallyltryptamine

Add links
From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by Wolren (talk | contribs) at 22:00, 26 November 2025 (added 3D image). The present address (URL) is a permanent link to this version.
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Propylallyltryptamine
Clinical data
Other namesPALT; N-Propyl-N-allyltryptamine; ASR-3004; ASR3004
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code
  • None
Identifiers
  • N-[2-(1H-indol-3-yl)ethyl]-N-prop-2-enylpropan-1-amine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC16H22N2
Molar mass242.366 g·mol−1
3D model (JSmol)
  • CCCN(CCC1=CNC2=CC=CC=C21)CC=C
  • InChI=1S/C16H22N2/c1-3-10-18(11-4-2)12-9-14-13-17-16-8-6-5-7-15(14)16/h3,5-8,13,17H,1,4,9-12H2,2H3
  • Key:BPHDZENPKNMIRD-UHFFFAOYSA-N

Propylallyltryptamine (PALT), also known as N-propyl-N-allyltryptamine or by its developmental code name ASR-3004, is a serotonin receptor modulator of the tryptamine family.[1] It is an asymmetrical analogue of dipropyltryptamine (DPT) and diallyltryptamine (DALT).[1] The drug is a non-selective serotonin receptor agonist, including of the serotonin 5-HT1B, 5-HT2A, 5-HT2B, and 5-HT6 receptors, but not of the serotonin 5-HT1A receptor.[1] It is also a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The chemical synthesis of PALT has been described.[1] A notable analogue of PALT is iPALT (ASR-3003).[1] PALT was patented by the Alexander Shulgin Research Institute (ASRI) in 2024.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g US 20240277665A1, Daley PF, Cozzi NV, Callaway WB, "Asymmetric allyl tryptamines", issued 4 March 2024, assigned to Alexander Shulgin Research Institute Inc. 
Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Propylallyltryptamine&oldid=1324312697"